The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
 
Erika P. Hamilton
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Judy S. Wang
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - Acerta Pharma/AstraZeneca (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen Research & Development (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Vigeo Therapeutics (Inst); Xencor (Inst)
 
Timothy J. Pluard
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Genentech; H3 Biomedicine; Macrogenics; Novartis; Pfizer; Seagen
Speakers' Bureau - Genentech/Roche; Immunomedics; Novartis; Pfizer; Seagen
Research Funding - Seagen (Inst)
 
Stephen R. D. Johnston
Honoraria - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Puma Biotechnology
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
Expert Testimony - Novartis
 
Aki Morikawa
Consulting or Advisory Role - Eisai; Lilly
Research Funding - Eisai (Inst); Eisai (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Merrimack (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Tempus (Inst)
Other Relationship - Taiho Pharmaceutical
 
Elizabeth Claire Dees
Consulting or Advisory Role - G1 Therapeutics; Novartis (I); Strata Oncology
Research Funding - Bayer; Cerulean Pharma; Genentech/Roche; H3 Biomedicine; Lilly; Merck; Meryx Pharmaceuticals; Novartis; Pfizer
Travel, Accommodations, Expenses - G1 Therapeutics
 
Robert Hugh Jones
No Relationships to Disclose
 
Barbara B. Haley
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst)
 
Anne Caroline Armstrong
Stock and Other Ownership Interests - AstraZeneca (I)
Travel, Accommodations, Expenses - Lilly; MSD
 
Adam Louis Cohen
Research Funding - Abbvie (Inst); Acrotech Biopharma (Inst); AstraZeneca (Inst); BioMimetix (Inst); Bristol-Myers Squibb (Inst); Cantex (Inst); Daiichi Sankyo (Inst); Diffusion Pharmaceuticals (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merrimack (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Pamela N. Munster
Leadership - Alessa Therapeutics; EpiAxis Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; OnKure
Honoraria - CStone Pharmaceuticals; Epigene; Prometheus (I)
Consulting or Advisory Role - Array BioPharma (I); AstraZeneca; Athenex; AtlasMedx; BeiGene; BMSi (I); GenomeSmart; IQvia (I); Jubilant Pharmaceuticals; NeoHealth (I); RasCal; RasCal
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
 
Gail Lynn Shaw Wright
Stock and Other Ownership Interests - Macrogenics (I); Odonate Therapeutics; Puma Biotechnology; Roche
Research Funding - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; E.R. Squibb Sons, LLC; G1 Therapeutics; Genentech; H3 Biomedicine; Incyte; Innocrin Pharma; Janssen; Lilly; Medivation; Novartis; Nucana; Pfizer; Seagen; Taiho Pharmaceutical; Tesaro
 
Fadi Kayali
No Relationships to Disclose
 
Manav Korpal
Employment - H3 Biomedicine
Patents, Royalties, Other Intellectual Property - H3 Biomedicine
 
Jianjun Alan Xiao
Employment - H3 Biomedicine; Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - H3 Biomedicine
 
Jenny Long
Employment - H3 Biomedicine
 
Benoit Destenaves
Employment - AstraZeneca; H3 Biomedicine
Stock and Other Ownership Interests - AstraZeneca
 
Lei Gao
Employment - Eisai
Stock and Other Ownership Interests - Eisai; Vertex
Research Funding - Eisai; Vertex
 
Antonio Gualberto
Employment - H3 Biomedicine; H3 Biomedicine; Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
Patents, Royalties, Other Intellectual Property - Patent of HRAS mutation as biomarker for farnesyl transferase inhibitor treatment in HNSCC
Travel, Accommodations, Expenses - Kura Oncology
 
Dejan Juric
Consulting or Advisory Role - Eisai; EMD Serono; Genentech; Ipsen; MapKure; Novartis; Petra Pharma; Syros Pharmaceuticals; Vibliome Therapeutics
Research Funding - Amgen (Inst); Eisai (Inst); EMD Serono (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Placon (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)